Shopping Cart
- Remove All
Your shopping cart is currently empty
HDAC-IN-36 is an orally active HDAC (histone deacetylase) inhibitor with an IC50 value of 11.68 nM for HDAC6. HDAC-IN-36 induces apoptosis, autophagy and inhibits migration. HDAC-IN-36 exhibits antitumor and antimetastatic effects and can be used to study breast cancer. HDAC-IN-36 exhibits antitumor and antimetastatic effects and can be used to study breast cancer.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks |
| Description | HDAC-IN-36 is an orally active HDAC (histone deacetylase) inhibitor with an IC50 value of 11.68 nM for HDAC6. HDAC-IN-36 induces apoptosis, autophagy and inhibits migration. HDAC-IN-36 exhibits antitumor and antimetastatic effects and can be used to study breast cancer. HDAC-IN-36 exhibits antitumor and antimetastatic effects and can be used to study breast cancer. |
| Targets&IC50 | HDAC7:>1000 nM, HDAC6:11.68 nM, HDAC1:86.93 nM, HDAC11:>1000 nM, HDAC2:97.32 nM, HDAC8:378.2 nM, HDAC9:>1000 nM, HDAC4:>1000 nM, HDAC5:>1000 nM, HDAC10:13.24 nM, HDAC3:79.17 nM |
| Molecular Weight | 537.65 |
| Formula | C29H39N5O5 |
| Cas No. | 2482992-54-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.